The announcement came two days prior to the U.S. Drug Enforcement Agency (DEA)’s court-mandated response to a lawsuit brought by a cannabis researcher.
The petitioner, Dr. Sue Sisley, heads the Scottsdale Research Institute in Arizona. Dr. Sisley is seemingly frustrated by the University of Mississippi, inexplicably having the monopoly on federally-approved medical cannabis for research purposes. She believes the cannabis “Ole Miss” disseminates to other researchers is low-quality, which could detrimentally impact their research.
A response to the mandamus petition was filed on behalf of one of the defendants in the suit, Attorney General William P. Barr, by Assistant Attorney General William H. Hunt, on August 28, in the United States Court of Appeals for the District of Columbia.
The government’s response states that “If an applicant seeks to manufacture a schedule I or schedule II controlled substance ‘for use only in a clinical trial,’ the Administrator will ‘issue a notice of application not later than 90 days after the application is accepted for filing.’” [Read more at Forbes]